1. Birch J.M. Epidemiology of Pediatric Liver Tumors. 2011. P. 15 - 26.

2. Hiyama E. Pediatric hepatoblastoma: diagnosis and treatment.//Transl. Pediatr. 2014. Vol. 3, N 4. P. 293 - 299.

3. Isaacs H. Fetal and neonatal hepatic tumors//Journal of Pediatric Surgery. 2007. Vol. 42, N 11. P. 1797 - 1803.

4. Malogolowkin M.H. Treatment of hepatoblastoma: the North American cooperative group experience//Front. Biosci. 2012. Vol. E4, N 1. P. 1717.

5. Tomlinson G.E., Kappler R. Genetics and epigenetics of hepatoblastoma//Pediatric Blood and Cancer. 2012. Vol. 59, N 5. P. 785 - 792.

6. Perilongo G., Malogolowkin M., Feusner J. Hepatoblastoma clinical research: Lessons learned and future challenges//Pediatric Blood and Cancer. 2012. Vol. 59, N 5. P. 818 - 821.

7. Trobaugh-Lotrario A.D., Katzenstein H.M. Chemotherapeutic approaches for newly diagnosed hepatoblastoma: Past, present, and future strategies//Pediatric Blood and Cancer. 2012. Vol. 59, N 5. P. 809 - 812.

8. Malogolowkin M.H. et al. Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: A report from the Children's Oncology Group//J. Clin. Oncol. 2011. Vol. 29, N 24. P. 3301 - 3306.

9. Ortega J.A. et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group.//J. Clin. Oncol. 2000. Vol. 18, N 14. P. 2665 - 2675.

10. J. et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: Final results of the SIOPEL-3HR study//J. Clin. Oncol. 2010. Vol. 28, N 15. P. 2584 - 2590.

11. Zsiros J. et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): A prospective, single-arm, feasibility study//Lancet Oncol. 2013. Vol. 14, N 9. P. 834 - 842.

12. Perilongo G. et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma//N. Engl. J. Med. Massachussetts Medical Society, 2009. Vol. 361, N 17. P. 1662 - 1670.

13. Aronson D.C. et al. The treatment of hepatoblastoma: Its evolution and the current status as per the SIOPEL trials//Journal of Indian Association of Pediatric Surgeons. Medknow Publications, 2014. Vol. 19, N 4. P. 201 - 207.

14. Towbin A.J. et al. 2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT)//Pediatric Radiology. Springer Verlag, 2018. Vol. 48, N 4. P. 536 - 554.

15. Roebuck D.J. et al. 2005 PRETEXT: A revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group//Pediatric Radiology. 2007. Vol. 37, N 2. P. 123 - 132.

16. Детская онкология. Национальное руководство. Под ред. М.Д. Алиева, В.Г. Полякова, Г.Л. Менткевича, С.А. Маяковой. М.: Издательская группа РОНЦ. Практическая медицина, 2012. 684 p.

17. Nakagawara A. et al. Hepatoblastoma producing both alpha-fetoprotein and human chorionic gonadotropin. Clinicopathologic analysis of four cases and a review of the literature//Cancer. 1985. Vol. 56, N 7. P. 1636 - 1642.

18. Wu J.-F. et al. Prognostic roles of pathology markers immunoexpression and clinical parameters in Hepatoblastoma//J. Biomed. Sci. BioMed Central Ltd., 2017. Vol. 24, N 1. P. 62.

19. Онкология. Национальное руководство. Под редакцией В.И. Чиссова, М.И. Давыдова. ГЭОТАР-Медицина, 2014. 1072 p.

20. Waters A.M. et al. A Synopsis of Pediatric Patients With Hepatoblastoma and Wilms Tumor: NSQIP-P 2012 - 2016//J. Surg. Res. Academic Press Inc., 2019. Vol. 244. P. 338 - 342.

21. I Tortajada J. et al. Factores de riesgo para los tumores hep ticos malignos pedi tricos//An. Pediatr. Elsevier Doyma, 2008. Vol. 68, N 4. P. 377 - 384.

22. M. et al. Malignancies in children with human immunodeficiency virus type 1 infection. The Italian Multicenter Study on Human Immunodeficiency Virus Infection in Children//Cancer. 1991. Vol. 68, N 11. P. 2473 - 2477.

23. Sharma D., Subbarao G., Saxena R. Hepatoblastoma//Semin. Diagn. Pathol. W.B. Saunders, 2017. Vol. 34, N 2. P. 192 - 200.

24. Haas J.E., Feusner J.H., Finegold M.J. Small cell undifferentiated histology in hepatoblastoma may be unfavorable.//Cancer. 2001. Vol. 92, N 12. P. 3130 - 3134.

25. Fazlollahi L. et al. Malignant rhabdoid tumor, an aggressive tumor often misclassified as small cell variant of hepatoblastoma//Cancers (Basel). MDPI AG, 2019. Vol. 11, N 12.

26. Bertolini P. et al. Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss//J. Pediatr. Hematol. Oncol. 2004. Vol. 26, N 10. P. 649 - 655.

27. Hu H.M. et al. Detection of Subclinical Anthracyclines' Cardiotoxicity in Children with Solid Tumor//Chin. Med. J. (Engl). Wolters Kluwer Medknow Publications, 2018. Vol. 131, N 12. P. 1450 - 1456.

28. Pakakasama S., Tomlinson G.E. Genetic predisposition and screening in pediatric cancer//Pediatric Clinics of North America. 2002. Vol. 49, N 6. P. 1393 - 1413.

29. Sumazin P. et al. Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups//Hepatology. John Wiley and Sons Inc., 2017. Vol. 65, N 1. P. 104 - 121.

30. Lawson C.E. et al. Genetic Counselor Practices Involving Pediatric Patients with FAP: an Investigation of their Self-Reported Strategies for Genetic Testing and Hepatoblastoma Screening//J. Genet. Couns. Springer New York LLC, 2017. Vol. 26, N 3. P. 586 - 593.

31. Meyers R.L. et al. Predictive power of pretreatment prognostic factors in children with hepatoblastoma: A report from the Children's Oncology Group//Pediatr. Blood Cancer. 2009. Vol. 53, N 6. P. 1016 - 1022.

32. Meyers R.L. et al. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration//Lancet Oncol. Lancet Publishing Group, 2017. Vol. 18, N 1. P. 122 - 131.

33. Dall'Igna P. et al. Hepatoblastoma in children aged less than six months at diagnosis: A report from the SIOPEL group//Pediatr. Blood Cancer. John Wiley and Sons Inc., 2018. Vol. 65, N 1.

34. Sunil B.J. et al. Surgical resection for hepatoblastoma-updated survival outcomes//J. Gastrointest. Cancer. Humana Press Inc., 2018. Vol. 49, N 4. P. 493 - 496.

35. Adamson P.C. et al. Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear-medicine-based estimates of renal function//Pediatr. Blood Cancer. John Wiley and Sons Inc., 2019. Vol. 66, N 6. P. e27672.

36. Chybicka A. et al. [G-CSF and GM-CSF in treatment of neutropaenia after chemotherapy in children with neoplasms].//Med. Wieku Rozwoj. 2000. Vol. 4, N 1 Suppl 2. P. 121 - 129.

37. Prasad P., Nania J.J., Shankar S.M. Pneumocystis pneumonia in children receiving chemotherapy//Pediatr. Blood Cancer. 2008. Vol. 50, N 4. P. 896 - 898.

38. Kooijmans E.C.M. et al. Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer//Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2019. Vol. 2019, N 3.

39. Lanvers-Kaminsky C., Ciarimboli G. Pharmacogenetics of drug-induced ototoxicity caused by aminoglycosides and cisplatin//Pharmacogenomics. Future Medicine Ltd., 2017. Vol. 18, N 18. P. 1683 - 1695.

40. August D.A., Huhmann M.B. A.S.P.E.N. Clinical guidelines: Nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation//Journal of Parenteral and Enteral Nutrition. JPEN J Parenter Enteral Nutr, 2009. Vol. 33, N 5. P. 472 - 500.

41. Isenring E., Elia M. Which screening method is appropriate for older cancer patients at risk for malnutrition?//Nutrition. Elsevier Inc., 2015. Vol. 31, N 4. P. 594 - 597.

42. Martin L. et al. Diagnostic criteria for the classification of cancer-associated weight loss//J. Clin. Oncol. American Society of Clinical Oncology, 2015. Vol. 33, N 1. P. 90 - 99.

43. Manary M.J., Sandige H.L. Management of acute moderate and severe childhood malnutrition//BMJ. BMJ, 2008. Vol. 337, N 7680. P. 1227 - 1230.

44. van den Broeck J., Eeckels R., Massa G. Validity of Single-Weight Measurements to Predict Current Malnutrition and Mortality in Children//J. Nutr. 1996. Vol. 126, N 1. P. 113 - 120.

45. Meijers J.M.M. et al. Nutritional care; do process and structure indicators influence malnutrition prevalence over time?//Clin. Nutr. Churchill Livingstone, 2014. Vol. 33, N 3. P. 459 - 465.

46. Muscaritoli M. et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics"//Clin. Nutr. Clin Nutr, 2010. Vol. 29, N 2. P. 154 - 159.

47. Kondrup J. et al. ESPEN guidelines for nutrition screening 2002//Clin. Nutr. Churchill Livingstone, 2003. Vol. 22, N 4. P. 415 - 421.

48. Arends J. et al. ESPEN guidelines on nutrition in cancer patients//Clin. Nutr. Churchill Livingstone, 2017. Vol. 36, N 1. P. 11 - 48.

49. Joosten K.F.M., Kerklaan D., Verbruggen S.C.A.T. Nutritional support and the role of the stress response in critically ill children//Current Opinion in Clinical Nutrition and Metabolic Care. Lippincott Williams and Wilkins, 2016. Vol. 19, N 3. P. 226 - 233.

50. Koletzko B. et al. Guidelines on Paediatric Parenteral Nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), Supported by the European Society of Paediatri//Journal of Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr, 2005. Vol. 41, N SUPPL. 2. 87 p.

51. Tanner L. et al. Cancer Rehabilitation in the Pediatric and Adolescent/Young Adult Population//Seminars in Oncology Nursing. Elsevier Inc, 2020. Vol. 36, N 1. P. 150984.

52. Yang W. et al. Analysis of factors related to recurrence of paediatric hepatoblastoma - A single Centre retrospective study//BMC Pediatr. BioMed Central Ltd., 2019. Vol. 19, N 1.

53. D. et al. Towards an international pediatric liver tumor consensus classification: Proceedings of the Los Angeles COG liver tumors symposium//Modern Pathology. 2014. Vol. 27, N 3. P. 472 - 491.

54. Knight K.R. et al. Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group//J. Clin. Oncol. 2017. Vol. 35, N 4. P. 440 - 445.

55. Meyers RL, Maibach R, Hiyama E, B, Krailo M, Rangaswami A, Aronson DC, Malogolowkin MH, Perilongo G, von Schweinitz D, Ansari M, Lopez-Terrada D, Tanaka Y, Alaggio R, Leuschner I, Hishiki T, Schmid I, Watanabe K, Yoshimura K, Feng Y, Rinaldi E, Saraceno D, Derosa M, Czauderna P. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children"s Hepatic tumors International Collaboration. Lancet Oncol. 2017 Jan; 18(1): 122 - 131. doi: 10.1016/S1470-2045(16)30598-8. Epub 2016 Nov 22. PMID: 27884679; PMCID: PMC5650231.

56. Trobaugh-Lotrario AD, Maibach R, Aronson DC, Rangaswami A, B, O"Neill AF, Schmid I, Ansari M, Hishiki T, Ranganathan S, Alaggio R, de Krijger RR, Tanaka Y, Cho SJ, Vokuhl C, Maxwell R, Krailo M, Hiyama E, Czauderna P, Finegold M, Feusner JH, Malogolowkin MH, Meyers RL, Lopez-Terrada D. Outcomes of Patients Treated for Hepatoblastoma with Low Alpha-Fetoprotein and/or Small Cell Undifferentiated Histology: A Report from the Children"s Hepatic Tumors International Collaboration (CHIC). Cancers (Basel). 2023 Jan 11; 15(2): 467. doi: 10.3390/cancers15020467. PMID: 36672416; PMCID: PMC9857147.

57. Allen ME, Kopp BJ, Erstad BL. Stress ulcer prophylaxis in the postoperative period. Am J Health Syst Pharm. 2004 Mar 15; 61(6): 588 - 96. doi: 10.1093/ajhp/61.6.588;

58. Sarawagi R, Sundar S, Raghuvanshi S, Gupta SK, Jayaraman G. Common and Uncommon Anatomical Variants of Intrahepatic Bile Ducts in Magnetic Resonance Cholangiopancreatography and its Clinical Implication. Pol J Radiol. 2016 May 26; 81: 250 - 5. doi: 10.12659/PJR.895827

59. Gupta M, Choudhury PS, Singh S, Hazarika D. Liver Functional Volumetry by Tc-99m Mebrofenin Hepatobiliary Scintigraphy before Major Liver Resection: A Game Changer. Indian J Nucl Med. 2018 Oct-Dec; 33(4): 277 - 283. doi: 10.4103/ijnm.IJNM_72_18;

60. Vasudevan SA, Meyers RL, Finegold MJ, D, Ranganathan S, Dunn SP, Langham MR, McGahren ED, Tiao GM, Weldon CB, Malogolowkin MH, Krailo MD, Piao J, Randazzo J, Towbin AJ, BethMcCarville M, O"Neill AF, Furman WL, Rodriguez-Galindo C, Katzenstein HM. Outcomes of children with well-differentiated fetal hepatoblastoma treated with surgery only: Report from Children"s Oncology Group Trial, AHEP0731. J Pediatr Surg. 2022 Oct; 57(10): 251 - 256. doi: 10.1016/j.jpedsurg.2022.05.022. Epub 2022 Jun 9. PMID: 35810020; PMCID: PMC9474653.

61. Liu S, Feng J, Ren Q, Qin H, Yang W, Cheng H, Yao X, Xu J, Han J, Chang S, Yang S, Mou J, Lin Y, He L, Wang H. Evaluating the clinical efficacy and limitations of indocyanine green fluorescence-guided surgery in childhood hepatoblastoma: A retrospective study. Photodiagnosis Photodyn Ther. 2023 Dec; 44: 103790. doi: 10.1016/j.pdpdt.2023.103790. Epub 2023 Sep 9. PMID: 37696318.

62. Lake CM, Bondoc AJ, Dasgupta R, Jenkins TM, Towbin AJ, Smith EA, Alonso MH, Geller JI, Tiao GM. Indocyanine green is a sensitive adjunct in the identification and surgical management of local and metastatic hepatoblastoma. Cancer Med. 2021 Jul; 10(13): 4322 - 4343. doi: 10.1002/cam4.3982. Epub 2021 Jun 12. PMID: 34117727; PMCID: PMC8267136.

63. Hiyama E. Fluorescence Image-Guided Navigation Surgery Using Indocyanine Green for Hepatoblastoma. Children (Basel). 2021 Nov 5; 8(11): 1015. doi: 10.3390/children8111015. PMID: 34828728; PMCID: PMC8617810.;

64. Yamada Y, Ohno M, Fujino A, et al. Fluorescence-Guided Surgery for Hepatoblastoma with Indocyanine Green. Cancers (Basel). 2019; 11(8): 1215. Published 2019 Aug 20. Doi: 10.3390/cancers11081215;

65. Takahashi N, Yamada Y, Hoshino K, Kawaida M, Mori T, Abe K, Fujimura T, Matsubara K, Hibi T, Shinoda M, Obara H, Isshiki K, Shima H, Shimada H, Kameyama K, Fuchimoto Y, Kitagawa Y, Kuroda T. Living Donor Liver Re-Transplantation for Recurrent Hepatoblastoma in the Liver Graft following Complete Eradication of Peritoneal Metastases under Indocyanine Green Fluorescence Imaging. Cancers (Basel). 2019 May 26; 11(5): 730. doi: 10.3390/cancers11050730. PMID: 31130716; PMCID: PMC6562613.)

66. Протокол PHITT Paediatric Hepatic International Tumour Trial. https://s3.observador.pt/wp-content/uploads/2019/09/09113804/phitt.pdf

67. Zsiros J, Brugieres L, Brock P, Roebuck D, Maibach R, Zimmermann A, Childs M, Pariente D, Laithier V, Otte JB, Branchereau S, Aronson D, Rangaswami A, Ronghe M, Casanova M, Sullivan M, Morland B, Czauderna P, Perilongo G; International Childhood Liver Tumours Strategy Group (SIOPEL). Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol. 2013 Aug; 14(9): 834 - 42. doi: 10.1016/S1470-2045(13)70272-9. Epub 2013 Jul 4. PMID: 23831416; PMCID: PMC3730732.

68. Протокол SIOPEL-3. Исследования опухолей печени. https://nodgo.org/sites/default/files/SIOPEL%203%20рус.pdf

69. Ликарь Ю.Н., Ахаладзе Д.Г., Румянцев А.Г. Гепатобилиарная сцинтиграфия в предоперационной оценке функции планируемого остатка печени (обзор литературы и собственные примеры). Российский журнал детской гематологии и онкологии (РЖДГиО). 2020; 7(1): 62 - 69. https://doi.org/10.21682/2311-1267-2020-7-1-62-69

70. Chaurasiya, Kailash PhD; Kireeva, Elena MD; Yadgarov, Mikhail MD; Akhaladze, Dmitry PhD; Likar, Yury PhD. "Role of Preoperative Hepatobiliary Scintigraphy in Children Requiring Liver Resection". Clinical Nuclear Medicine Jul 1; 48(7): 581 - 585, April 18, 2023. DOI: 10.1097/RLU.0000000000004660

71. Apellaniz-Ruiz M, Segni M, Kettwig M, S, Pelletier D, Nguyen VH, Wagener R, C, Muchantef K, Bouron-Dal Soglio D, Sabbaghian N, Wu MK, Zannella S, Fabian MR, Siebert R, Menke J, Priest JR, Foulkes WD. Mesenchymal Hamartoma of the Liver and DICER1 Syndrome. N Engl J Med. 2019 May 9; 380(19): 1834 - 1842. doi: 10.1056/NEJMoa1812169. PMID: 31067372.

72. Stringer MD, Alizai NK. Mesenchymal hamartoma of the liver: a systematic review. J Pediatr Surg. 2005 Nov; 40(11): 1681 - 90. doi: 10.1016/j.jpedsurg.2005.07.052. PMID: 16291152.]

73. Apellaniz-Ruiz M, Segni M, Kettwig M, Gl er S, Pelletier D, Nguyen VH, Wagener R, C, Muchantef K, Bouron-Dal Soglio D, Sabbaghian N, Wu MK, Zannella S, Fabian MR, Siebert R, Menke J, Priest JR, Foulkes WD. Mesenchymal Hamartoma of the Liver and DICER1 Syndrome. N Engl J Med. 2019 May 9; 380(19): 1834 - 1842. doi: 10.1056/NEJMoa1812169. PMID: 31067372.

74. Stringer MD, Alizai NK. Mesenchymal hamartoma of the liver: a systematic review. J Pediatr Surg. 2005 Nov; 40(11): 1681 - 90. doi: 10.1016/j.jpedsurg.2005.07.052. PMID: 16291152.

75. Приказ МЗ РФ от 23.09.2020 N 1008н "Об утверждении порядка обеспечения пациентов лечебным питанием"

76. Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, E, Isenring E, Kaasa S, Krznaric Z, Laird B, Larsson M, Laviano A, S, Oldervoll L, Ravasco P, Solheim TS, Strasser F, de van der Schueren M, Preiser JC, Bischoff SC. ESPEN practical guideline: Clinical Nutrition in cancer. Clin Nutr. 2021; 40(5): 2898 - 2913. doi: 10.1016/j.clnu.2021.02.005

77. Вашура А.Ю. Нутритивная недостаточность, ее причины и пути коррекции у детей с опухолями ЦНС на этапе активной терапии и после ее окончания. Фарматека. 2019; 26 (10): 8 - 14

78. Парентеральное и энтеральное питание: национальное руководство/под ред. М.Ш. Хубутия, Т.С. Поповой, А.И. Салтанова. - М.: ГЭОТАР-Медиа, 2014. - 800 с.

79. Mehta NM, Corkins MR, Lyman B, Malone A, Goday PS, Carney LN, Monczka JL, Plogsted SW, Schwenk WF; American Society for Parenteral and Enteral Nutrition Board of Directors. Defining pediatric malnutrition: a paradigm shift toward etiology-related definitions. JPEN J Parenter Enteral Nutr. 2013; 37(4): 460 - 81. doi: 10.1177/0148607113479972

80. Алымова Ю.А., Вашура А.Ю. Адекватная оценка нутритивного статуса в детской онкологии и гематологии - первый этап нутритивного сопровождения. Трудный пациент. 2019; Т. 17. N 8 (9). С. 54 - 59.

81. Martin L. et al. Diagnostic criteria for the classification of cancer-associated weight loss//J. Clin. Oncol. American Society of Clinical Oncology, 2015. Vol. 33, N 1. P. 90 - 99

82. Kondrup J. et al. ESPEN guidelines for nutrition screening 2002//Clin. Nutr. Churchill Livingstone, 2003. Vol. 22, N 4. P. 415 - 421; Arends J. et al. ESPEN guidelines on nutrition in cancer patients//Clin. Nutr. Churchill Livingstone, 2017. Vol. 36, N 1. P. 11 - 48

83. Вашура АЮ, Кучер МА, Ковтун ТА, Алымова ЮА, Литвинов ДВ, Зубаровская ЛС, Кулагин АД. Роль и актуальность нутрициологического диагноза в онкопедиатрии. Медицинский Совет. 2023; (12): 99 - 109

84. Yaprak D.S, B., A.A., M. Assessment of nutritional status in children with cancer: Significance of arm anthropometry and serum visceral proteins. Pediatr Blood Cancer. 2021; 68(1): 28752

85. Методические указания. Порядок проведения клинических исследований для оценки эффективности специализированной пищевой продукции диетического лечебного и диетического профилактического питания/ФГБУН "ФИЦ питания и биотехнологии", Роспотребнадзор, Минздрав России, ФГБУН "ФНЦГ им. Ф.Ф. Эрисмана" Роспотребнадзора. - Москва. - 2023. - 28 с.

86. Методическое руководство. Стандарты лечебного питания/ФГБУН "ФИЦ питания и биотехнологии". - Москва. - 2017. - 338 с.

87. Вашура А.Ю., Пятаева А.А., Карелин А.Ф. Питание и нутритивная поддержка детей со злокачественными новообразованиями после завершения лечения: основные аспекты. Вопросы детской диетологии. 2022; 20(6): 64 - 70

88. Rayar M., Webber C.E., Nayiager T., Sala A., Barr R.D. Sarcopenia in children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2013; 35: 98 - 102; Pietila S., Makipernaa A., Sievanen H., Koivisto A.M., Wigren T., Lenko H.L. Obesity and metabolic changes are common in young childhood brain tumor survivors. Pediatr Blood Cancer. 2009; 52: 853 - 9

89. Joosten K, Embleton N, Yan W, Senterre T; ESPGHAN/ESPEN/ESPR/CSPEN working group on pediatric parenteral nutrition. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Energy. Clin Nutr. 2018; 37(6 Pt B): 2309 - 2314. doi: 10.1016/j.clnu.2018.06.944

90. Особенности нутриционной поддержки больных в педиатрии. В кн.: Клиническое питание больных в интенсивной медицине: практическое руководство/под ред. Луфта В.М., Багненко С.Ф., издание второе, дополненное. СПб.: Арт-Экспресс, 2013 - 460.

91. Парентеральное и энтеральное питание детей. Практические рекомендации. Под ред. Ерпулевой Ю.В., Чубаровой А.И., Чугуновой Ю.Л. ГЭОТАР-Медиа, 2016 г. 304 с.; Arends J. et al. ESPEN guidelines on nutrition in cancer patients//Clin. Nutr. Churchill Livingstone, 2017. Vol. 36, N 1. P. 11 - 48

92. Современные рекомендации по питанию детей/под ред. Проф. Ю.Г. Мухиной, проф. И.Я. Коня. - М.: ИД "МЕДПРАКТИКА-М", 2010, 568 с.

93. Ерпулева Ю.В. Парентеральное питание у детей Российский вестник детской хирургии, анестезиологии и реаниматологии. 2018; 8(1): 49 - 56

94. Viani K., Trehan A., Manzoli B., Schoeman J. Assessment of nutritional status in children with cancer: A narrative review. Pediatr Blood Cancer. 2020; 67 Suppl 3: e28211. https://doi:10.1002/pbc.2821

95. Koletzko B., Goulet O., Hunt J., Krohn K., Shamir R. for the Parenteral Nutrition Guidelines Working Group. Guidelines on Paediatric Parenteral nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), Supported by the European Society of Paeditric Research (ESPR). J. Pediatr. Gastroenterol. Nutr. 2005; 41: Suppl. 2: S1 - S87. DOI: 10.1097/01. mpg.0000181841.07090.f4

96. Bercovitz RS., Josephson CD. Transfusion considerations in pediatric hematology and oncology patients. Hematol Oncol Clin North Am. 2016; 30(3): 695 - 709. doi: 10.106/j.hoc.2016.01.010.

97. Steiner ME, Zantek ND, Stanworth SJ, Parker RI, et al. Recommendations on RBC Transfusion Support in Children With Hematologic and Oncologic Diagnoses From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative. Pediatr Crit Care Med. 2018 Sep; 19 (9S Suppl 1): 149 - 156.

98. Shah N., Andrews J., Goodnough LT. Transfusions for anemia in adult and pediatric patients with malignancies. Blood Reviews. 2015; 29(5): 291 - 299. doi: 10.106/j.blre.2015.02.001

99. Nellis ME, Goel R, Karam O. Transfusion Management in Pediatric Oncology Patients. Hematol Oncol Clin North Am. 2019; 33(5): 903 - 913. doi: 10.1016/j.hoc.2019.05.011.

100. World Health Organization. (2021). Educational modules on clinical use of blood. https://www.who.int/publications/i/item/9789240033733

101. Долгов ВВ., Свирин ПВ. Лабораторная диагностика нарушений гемостаза. Москва: Триада, 2005 - с 150. ISBN 5-94789-114-x.

102. Кречетова А.В. Нарушение гемостаза при сепсисе у онкогематологических больных с миелотоксическим агранулоцитозом: автореф. Дис канд мед. наук. М.: Гематологический научный центр; 2011

103. Kozek-langenecker S.A., Afshari A., Albaladejo P., et al. Management of severe perioperative bleeding Guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2013; 30: 270 - 382. DOI: 10.1097/EJA.0b013e32835f4d5.

104. O"Shaughnessy D., Atterbury C., Bolton Maggs P., et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Hematol. 2004; 126(1): 11 - 28. DOI: 10.1111/j.1365-2141.2004.04972.x.

105. Галстян Г.М., Гапонова Т.В., Жибурт Е.Б., Балашова Е.Н., Берковский А.Л., Быстрых О.А., Купряшов А.А., Оловникова Н.И., Ошоров А.В., Рыбка М.М., Троицкая В.В., Буланов А.Ю., Журавель С.В., Лубнин А.Ю., Мазурок В.А., Недомолкин С.В., Певцов Д.Э., Рогачевский О.В., Салимов Э.Л., Трахтман П.Е., Чжао А.В., Шерстнев Ф.С., Савченко В.Г. Клиническое использование криопреципитата. Гематология и трансфузиология. 2020; 65(1): 87 - 114. doi.org/10.35754/0234-5730-2020-65-1-87-114

106. Румянцев А.Г., Масчан А.А., Самочатова Е.В. Сопроводительная терапия и контроль инфекций при гематологических и онкологических заболеваниях. Москва: МЕДПРАКТИКА-М, 2009. 448 p.; Румянцев А.Г. Федеральные клинические рекомендации по организации оптимально венозного доступа у детей с гематологическими, онкологическими и иммунологическими заболеваниями./А.Г. Румянцев, А.А. Масчан, Д.Ш. Биккулова. - 2015.; Венозный катетер. Использование, уход, контроль, осложнения: учебное пособие/Сацук А.В., Солопова Г.Г., Щукин В.В., Литвинов Д.В., Пименова О.В. Климова Н.А., Щемелинская Ю.Л., Масчан А.А., Новичкова Г.А. - М. АО "Информатика", 2023. - 152 с.: ил. ISBN 978-5-6049537-2-3.;

107. Guidelines of the Italian Association of Pediatric Hematology and Oncology for the management of the central venous access devices in pediatric patients with onco-hematological disease/M. Cellini, A. Bergadano, A. Crocoli [et al.]//The Journal of Vascular Access. - 2022. - Vol. 23. - N 1. - P. 3 - 17

108. Central Venous Catheter Care for the Patient With Cancer: American Society of Clinical Oncology Clinical Practice Guideline/C.A. Schiffer, P. B. Mangu, J. C. Wade [et al.]//Journal of Clinical Oncology. - 2013. - Vol. 31. - Central Venous Catheter Care for the Patient With Cancer. - N 10. - P. 1357 - 1370

109. Guidelines of the Italian Association of Pediatric Hematology and Oncology for the management of the central venous access devices in pediatric patients with onco-hematological disease/M. Cellini, A. Bergadano, A. Crocoli [et al.]//The Journal of Vascular Access. - 2022. - Vol. 23. - N 1. - P. 3 - 17

110. Румянцев А.Г. Федеральные клинические рекомендации по организации оптимально венозного доступа у детей с гематологическими, онкологическими и иммунологическими заболеваниями./А.Г. Румянцев, А.А. Масчан, Д.Ш. Биккулова. - 2015

111. Лахин Р.Е. Клинические рекомендации ФАР Катетеризация сосудов под контролем ультразвука. Катетеризация сосудов под контролем ультразвука/Р.Е. Лахин, Д.В. Заболотский, Б.А. Теплых.

112. Gavecelt Consensus Statement on the Correct use of Totally Implantable Venous Access Devices for Diagnostic Radiology Procedures/G. Bonciarelli, S. Batacchi, R. Biffi [et al.]//The Journal of Vascular Access. - 2011. - Vol. 12. - N 4. - P. 292 - 305.; Randomized Clinical Trial Evaluating Complications and Complication-Related Removal of Arm-Situated Power-Injectable and Non-Power-Injectable Totally Implanted Venous Access Devices among Cancer Patients/B. Burbridge, C. Plewes, G. Stoneham [et al.]//Journal of Vascular and Interventional Radiology. - 2018. - Vol. 29. - N 5. - P. 648 - 656. e3.

113. Prevention and management of central venous catheter occlusion and thrombosis in children with cancer/R. Skinner, K. Koller, N. McIntosh [et al.]//Pediatric Blood & Cancer. - 2008. - Vol. 50. - N 4. - P. 826 - 830.; Risk for Health Care-Associated Bloodstream Infections in Pediatric Oncology Patients With Various Malignancies/C.B. Thurman, M. Abbott, J. Liu, E. Larson//Journal of Pediatric Oncology Nursing. - 2017. - Vol. 34. - N 3. - P. 196 - 202.

114. Cameron G. S. Central venous catheters for children with malignant disease: Surgical issues/G.S. Cameron//Journal of Pediatric Surgery. - 1987. - Vol. 22. - Central venous catheters for children with malignant disease. - N 8. - P. 702 - 704.

115. Cyanoacrylate Glue and Central Venous Access Device Insertion/M. Pittiruti, G. Scoppettuolo, A. Emoli [et al.]//Journal of the Association for Vascular Access. - 2016. - Vol. 21. - N 4. - P. 249.; Cyanoacrylate glue prevents early bleeding of the exit site after CVC or PICC placement/G. Scoppettuolo, M. Annetta, C. Marano [et al.]//Critical Care. - 2013. - Vol. 17. - N S2. - P. P174, cc12112.

116. [Experimental study on the chemico-physical interaction between a two-component cyanoacrylate glue and the material of PICCs/F. Di Puccio, D. Giacomarro, L. Mattei [et al.]//The Journal of Vascular Access. - 2018. - Vol. 19. - N 1. - P. 58 - 62.

117. Венозный катетер. Использование, уход, контроль, осложнения: учебное пособие/Сацук А.В., Солопова Г.Г., Щукин В.В., Литвинов Д.В., Пименова О.В. Климова Н.А., Щемелинская Ю.Л., Масчан А.А, Новичкова Г.А. - М. АО "Информатика", 2023. - 152 с.: ил. ISBN 978-5-6049537-2-3.;

118. Patel P. Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis.//Patel P, Robinson PD, Wahib N [et al]//Support Care Cancer. 2022 Nov; 30(11): 8855 - 8869. doi: 10.1007/s00520-022-07287-w

119. Hesketh, P.J. Antiemetics: ASCO Guideline Update/P.J. Hesketh, M.G. Kris, E. Basch [et al.]//J Clin Oncol. - 2020. - JCO2001296. - doi: 10.1200/JCO.20.01296

120. Patel, P. Prevention and treatment of anticipatory chemotherapy-induced nausea and vomiting in pediatric cancer patients and hematopoietic stem cell recipients: Clinical practice guideline update/P. Patel, P.D. Robinson, K.A. Devine [et al.]//Pediatr Blood Cancer. - 2021. - Vol. 68(5). - P. e28947. - doi: 10.1002/pbc.28947

121. Жуков, Н.В. Эффективность и безопасность малых доз оланзапина в профилактике тошноты и рвоты у детей и подростков, получающих высокоэметогенную химиотерапию. Промежуточные результаты рандомизированного исследования/Н.В. Жуков, Л.Л. Рабаева, Д.В. Литвинов//Вопросы гематологии/онкологии и иммунопатологии в педиатрии. - 2022. - N 4. - С. 70 - 82. doi: 10.24287/1726-1708-2022-21-4-70-82

122. Jain S. A randomized, open-label non-inferiority study to compare palonosetron and ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderate or high emetogenic chemotherapy/Jain S., Kapoor G, Koneru S, Vishwakarma G//Support Care Cancer - 2018 Sep; 26(9): 3091 - 3097. doi: 10.1007/s00520-018-4158-5

123. Patel P. Dexamethasone dosing for prevention of acute chemotherapy-induced vomiting in pediatric patients: A systematic review/Patel P, Olteanu A, Cabral S, Santesso N, Robinson PD, Dupuis LL.//Pediatr Blood Cancer. 2020 Dec; 67(12): e28716. doi: 10.1002/pbc.28716

124. Ramavath, D.N. Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy: Investigator-Initiated, Randomized, Open-Label Trial/D.N. Ramavath, V. Sreenivas, S. Vishwajeet [et al.]//Journal of Clinical Oncology. - 2020. - Vol. 38(32). - P. 3785 - 3793. - doi: 10.1200/JCO.20.00871

125. Chaudhary, N.K. Palonosetron is a Better Choice Compared with Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results from a Randomized Control Trial/N.K. Chaudhary, R.R. John, D. Boddu [et al.]//J Pediatr Hematol Oncol. - 2019. - Vol. 41(4). - P. 294 - 297. - doi: 10.1097/MPH.0000000000001357

126. Flank, J. Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children with Cancer/J. Flank, P.D. Robinson, M. Holdsworth [et al.]//Pediatr Blood Cancer. - 2016. - Vol. 63(7). - P. 1144 - 1151. - doi: 10.1002/pbc.25955.

127. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity and cost associated with febrile neutropenia in adult cancer patients. Cancer, 2006; 106(10): 2258 - 2266

128. Mikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cordonnier C et al. Aetiology and resistance in bacteriaemias among adult and paediatric haematology and cancer patients. Jornal of infection (2014), 68: 321 - 331

129. Lyman GH, Rolston KVI. How we treat febrile neutropenia in patients receiving cancer chemotherapy. Journal of oncology practice, 2010; 6(3): 149 - 152

130. Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference of Infections in Luekemia. Haematologica 2013; 98(12): 1826 - 1835

131. Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK et al. Antimicrobial prophycaxis and outpatient management of fever and neutropenia in adults treated for malignancy: american society of clinical oncology clinical practice guidline. American society of clinical oncology 2012, www.asco.org/guedlines/outpatient

132. Hakim H, Flynn PM, Knapp KM, Srivastava DK, Gaur AH. Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol, 2009; 31(9): 623 - 629

133. Tam CS, O"Reilly M, Andresen D, Lingaratnam S, Kelly A, Burbury K et al. Use of empiric antimicrobial therapy in neutripenic fever. Intern Med J, 2011; 41: 90 - 101

134. Miranda M., Nadel S. Pediatric Sepsis: a Summary of Current Definitions and Management Recommendations//Curr Pediatr Rep. Springer Nature, 2023. Vol. 11, N 2. P. 29 - 39.

135. Lehrnbecher T, Phillips R, Alexander S, Alvaro F, Carlesse F, Fisher B et al. Guidlenes for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol, 2012; 30(35): 4427 - 4438

136. Simon A. et al. Surveillance of bloodstream infections in pediatric cancer centers - what have we learned and how do we move on?//GMS Hyg Infect Control. German Medical Science, 2016. Vol. 11. P. Doc 11.

137. Bard J.D., TeKippe E.M.E. Diagnosis of Bloodstream Infections in Children//J Clin Microbiol. J Clin Microbiol, 2016. Vol. 54, N 6. P. 1418 - 1424.

138. Petty L.A. et al. Repeated Blood Cultures in Pediatric Febrile Neutropenia: Would Following the Guidelines Alter the Outcome?//Pediatr Blood Cancer. Pediatr Blood Cancer, 2016. Vol. 63, N 7. P. 1244 - 1249.

139. Scheler M. et al. Management of children with fever and neutropenia: results of a survey in 51 pediatric cancer centers in Germany, Austria, and Switzerland//Infection. Springer Science and Business Media Deutschland GmbH, 2020. Vol. 48, N 4. P. 607 - 618.

140. Vehreschild M.J.G.T. et al. A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies//J Antimicrob Chemother. J Antimicrob Chemother, 2014. Vol. 69, N 12. P. 3387 - 3392.

141. Jaiswal S.R. et al. Gut Colonization with Carbapenem-resistant Enterobacteriaceae Adversely Impacts the Outcome in Patients with Hematological Malignancies: Results of A Prospective Surveillance Study//Mediterr J Hematol Infect Dis. Catholic University in Rome, 2018. Vol. 10, N 1. P. 2018025.

142. Girmenia C. et al. Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey//Clin Infect Dis. Clin Infect Dis, 2017. Vol. 65, N 11. P. 1884 - 1896.

143. Klastersky J., Awada A, Paesmans M, Aoun M. Febrile neutropenia: a critical review of the initial management. CID, 2004; 39(1): 32 - 37

144. Morrissey C., Gilroy N., Macesic N., Walker P., Nanda-Rajah M. et al. Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014. Intern Med J, 2014; 44: 1298 - 1314.

145. Groll AH, Werner C, Tebbe J, Solopova G, Becker K et al. Pulmonale Infectionen in der und Oncologie. Monatsschr Kinderheilkd, 2011; 159: 233 - 241

146. Ruhnke M and Schwartz S. Recent developments in the management of invasive fungal infections in patients with oncohematological diseases. Ther Adv Hematol, 2016; 7(6): 345 - 359

147. Tissot F., Agrawai S., Pagano L., Petrikkos G., Groll A.H. et al. ECIL-6 Guidelines for the Treatment of Invasive Candidiasis, Aspergillosis and Mucormycosis in Liekemia and Hematopoietic Stem Cell Transplant Patients. Hematologica, 2017; 102: 433 - 444

148. Heussel C., Kauczor H., Heussel G., Fischer B., Begrich M. et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol, 1999; 17: 796 - 805.

149. Новичкова Г.А., Горонкова О.В., Балашов Д.Н., Байдильдина Д.Д., Жарикова Л.И. и др. Диагностика, клиника и лечение инвазивного аспергиллеза у детей с приобретенной апластической анемией: анализ 20 собственных случаев. Гематология и трансфузиология, январь 2005.

150. Ison M.G., Hirsch H.H. Community-Acquired Respiratory Viruses in Transplant Patients: Diversity, Impact, Unmet Clinical Needs//Clin Microbiol Rev. Clin Microbiol Rev, 2019. Vol. 32, N 4.

151. Hermann B. et al. Influenza virus infections in patients with malignancies - characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO)//European Journal of Clinical Microbiology & Infectious Diseases. Springer, 2017. Vol. 36, N 3. P. 565.

152. Солопова Г.Г., Цыганова Е.В., Кондрашова А.В., Гордеева Г.Н., Розанцева Е.В., Бегунова С.В., Воронин К.А., Копосова А.О., Новичкова Г.А. "Особенности течения новой коронавирусной инфекции COVID-19 у детей с онкологическими, онкогематологическими и тяжелыми иммунологическими заболеваниями. Опыт НМИЦ ДГОИ им. Дмитрия Рогачева". Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2021 т. 20 N 4: 89 - 99

153. Spruit J L, Knight T, Sweeney C, Salimnia H, S. Clostridium difficile infection in a children"s hospital with specific patterns among pediatric oncology and hematopoietic stem cell transplantation populations Pediatr Hematol Oncol. 2020 Apr; 37(3): 211 - 222. doi: 10.1080/08880018.2019.1711473

154. Tai E, Richardson LC, Townsend J, Howard E, Mcdonald LC Clostridium difficile infection among children with cancer Pediatr Infect Dis J. 2011 Jul; 30(7): 610 - 2.

155. Castagnola E., Ruberto E., Guarino A. Gastrointestinal and liver infections in children undergoing antineoplastic chemotherapy in the years 2000//World J Gastroenterol. Baishideng Publishing Group Inc, 2016. Vol. 22, N 25. P. 5853.

156. Maertens J.A. et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay//Clin Infect Dis. Clin Infect Dis, 2007. Vol. 44, N 10. P. 1329 - 1336.

157. Lehrnbecher T, Robinson PD, Fisher BT, Castagnola E, Groll AH, Steinbach WJ, Zaoutis TE, Negeri ZF, Beyene J, Phillips B, Sung L. Galactomannan, , and Polymerase Chain Reaction-Based Assays for the Diagnosis of Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2016 Nov 15; 63(10): 1340 - 1348. doi: 10.1093/cid/ciw592

158. Warris A, Lehrnbecher T Progress in the Diagnosis of Invasive Fungal Disease in Children Curr Fungal Infect Rep. 2017; 11(2): 35 - 44. doi: 10.1007/s12281-017-0274-9.

159. Gupta A, Capoor MR, Shende T, Sharma B, Mohindra R, Suri JC, Gupta DK. Comparative evaluation of galactomannan test with bronchoalveolar lavage and serum for the diagnosis of invasive aspergillosis in patients with hematological malignancies. J Lab Physicians. 2017 Oct - Dec; 9(4): 234 - 238. doi: 10.4103/JLP.JLP_127_16.

160. Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care. 2010; 14(6): R222. doi: 10.1186/cc9365

161. Duettmann W, Koidl C, Krause R, Lackner G, Woelfler A, Hoenigl M. Specificity of mannan antigen and anti-mannan antibody screening in patients with haematological malignancies at risk for fungal infection. Mycoses. 2016 Jun; 59(6): 374 - 8. doi: 10.1111/myc.12482

162. Chang CC, Harrison TS, Bicanic TA, Chayakulkeeree M, Sorrell TC, Warris A, et al. Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM.. Lancet Infect Dis. 2024 Feb 9: S1473 - 3099(23)00731-4. doi: 10.1016/S1473-3099(23)00731-4.

163. Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, et al. Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. J Clin Oncol. 2017 Jun 20; 35(18): 2082 - 2094. doi: 10.1200/JCO.2016.71.7017

164. Lehrnbecher T. et al. Guideline for the Management of Fever and Neutropenia in Pediatric Patients With Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update//J Clin Oncol. J Clin Oncol, 2023. Vol. 41, N 9. P. 1774 - 1785.

165. Lehrnbecher T. et al. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation//Lancet Oncol. Lancet Oncol, 2021. Vol. 22, N 6. P. e270 - e280.

164. Freifeld A.G. et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america//Clin Infect Dis. Clin Infect Dis, 2011. Vol. 52, N 4.

165. Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, et al. Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. J Clin Oncol. 2017 Jun 20; 35(18): 2082 - 2094. doi: 10.1200/JCO.2016.71.7017

166. Lehrnbecher T. et al. Guideline for the Management of Fever and Neutropenia in Pediatric Patients With Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update//J Clin Oncol. J Clin Oncol, 2023. Vol. 41, N 9. P. 1774 - 1785.

167. Lehrnbecher T. et al. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation//Lancet Oncol. Lancet Oncol, 2021. Vol. 22, N 6. P. e270 - e280.

168. Солопова Г.Г., Новичкова Г.А. Опыт внедрения алгоритма эмпирической антибактериальной терапии при развитии фебрильной нейтропении в Центре детской гематологии/онкологии//Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2017. Vol. 16, N 3. P. 35 - 47.

169. Lehrnbecher T. Treatment of fever in neutropenia in pediatric oncology patients Current Opinion in Pediatrics 31(1): p 35 - 40, February 2019. | DOI: 10.1097/MOP.0000000000000708

170. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H et al. Surviving sepsis campain: international guidlines for management of severe sepsis and septic shock, 2012. Intensive Care Med, 2013; 39(2): 165 - 228

171. Ferrer R. et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program//Crit Care Med. Crit Care Med, 2014. Vol. 42, N 8. P. 1749 - 1755.

172. Van Vliet M. et al. How prompt is prompt in daily practice? Earlier initiation of empirical antibacterial therapy for the febrile neutropenic patient//Eur J Cancer Care (Engl). Eur J Cancer Care (Engl), 2011. Vol. 20, N 5. P. 679 - 685.

173. Morales Castro D. et al. Pharmacokinetic Alterations Associated with Critical Illness//Clin Pharmacokinet. Adis, 2023. Vol. 62, N 2. P. 209 - 220.

174. Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H et al. Empirical versus antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis, 2009; 48: 1042 - 1051

175. Groll AH, Pana D, Lanternier F, Mesini A, Ammann RA 8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncol. 2021 Jun; 22(6): e254 - e269. doi: 10.1016/S1470-2045(20)30723-3

176. Солопова Г.Г., Масчан А.А., Новичкова Г.Г. "Рекомендации 2020 года по диагностике и терапии инвазивного аспергиллеза у детей с онкогематологическими заболеваниями". Вопросы гематологии/онкологии и иммунопатологии. 2020 т. 19 N 1, стр. 158 - 166

177. Dolton MJ, Ray JE, Chen Sh.A., Ng K., Pont LG and McLachlan AJ. Multicenter study of voriconasol pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother, 2012; 59(9): 4793 - 4799

178. Dolton MJ, Ray JE, Chen Sh.A., Ng K., Pont LG and McLachlan AJ. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother, 2012; 56(11): 5503 - 5510

179. De Pauw B., Walsh T.J., Donnelly J.P., Stevens E.E., Edwards J.E. et al. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis, 2008; 46(12): 1813 - 1821.

180. Blohm ME, D, Calaminus G, U. Alpha 1-fetoprotein (AFP) reference values in infants up to 2 years of age. Pediatr Hematol Oncol. 1998 Mar-Apr; 15(2): 135 - 42. doi: 10.3109/08880019809167228. PMID: 9592840.

181. Meyers AB, Towbin AJ, Serai S, Geller JI, Podberesky DJ. Characterization of pediatric liver lesions with gadoxetate disodium. Pediatr Radiol. 2011 Sep; 41(9): 1183 - 97. doi: 10.1007/s00247-011-2148-6. Epub 2011 Jun 24. PMID: 21701987.